Phase I/II Study of SCTB39G in Advanced Solid Tumours
ConditionAdvanced Malignant Solid Tumor
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorSinocelltech Ltd.
About this trial
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39G as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Eligibility criteria
Qualifiers
1.Voluntarily sign the informed consent form (ICF);
2.Male or female, ≥ 18 years and ≤ 70 years old;
3.Survival duration more than 3 months;
4.ECOG score ≤ 1 point;
Disqualifiers
1.Has participated in another clinical study within 4 weeks prior to the first dose;
2.Other malignancies diagnosed within 1 years prior to the enrollment;
3. Participants with brainstem, meningeal, spinal metastases, or compression; active central nervous system metastases;
4.NSCLC at high risk of bleeding; Obvious invasion of tumor into adjacent organs of esophageal lesions leads to high risk of bleeding or fistula,or participants after endotracheal stent implantation;
Trial design
Treatments tested in this trial
- SCTB39G
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov